We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




DNA Health Monitoring Campaign Launched

By LabMedica International staff writers
Posted on 11 Feb 2014
A DNA health test aims to assist in prevention of diseases associated with DNA damage and poor DNA repair.

The Berkeley-based startup, Exogen Biotechnology (CA, USA), has launched a unique citizen science campaign on Indiegogo, a global “crowd funding” website (San Francisco, CA, USA). More...
The campaign is based on a laboratory test, which measures DNA breaks, the most lethal type of DNA damage and a potentially key indicator for overall health conditions. Launched on January 25, 2013, the project raised USD 20,000 in “crowd funding” within its first three days.

The technology measures physical breaks in the DNA of cells, which commonly result from an individual's lifestyle, environmental toxins, or personal genetics. The startup from the Lawrence Berkeley National Laboratory envisions that its DNA health monitoring technology will one day be as commonplace as a cholesterol test. The DNA health test aims to assist in prevention of diseases associated with DNA damage and poor DNA repair.

Exogen is allowing the public to assist in funding its large-scale citizen scientist project as well as gain access to the technology that is not yet available to the public. Supporters receive a kit that allows funders to safely collect three blood samples via sterile finger pricks. Blood samples are then mailed to Exogen’s proprietary research lab and analyzed either as a one-time event or on a regular basis throughout the year. The blood is processed for DNA damage and the results are made available back to the funder, securely and privately via a protected web application.

The core team behind the project is comprised of Dr. Sylvain Costes and Dr. Jonathan Tang, who are experts in understanding the link between ionizing radiation, DNA damage, and cancer induction. They developed this leading-edge technology over the past 10 years at the Lawrence Berkeley National Laboratory.

Dr. Tang commented, “Breaks in our DNA occur frequently, and our bodies repair them every day. However, as we age, the efficiency of how our bodies repair DNA breaks seems to weaken. This decline in repair efficiency can lead to accumulation of unrepaired DNA or misrepaired DNA, which may result in unpredictable and potentially lethal genetic mutations. Exogen hopes that monitoring DNA for breaks will allow individuals to assess the impact of various lifestyles and environments on their overall health and aging.”

Related Links:

Exogen Biotechnology



New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Pipette Calibration System
Artel PCS®
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Capillary testing on the Atellica analyzers supports the most common laboratory testing needs (Photo courtesy of Siemens Healthineers)

Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers

Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.